Biocon commences clinical study of Itolizumab for Ulcerative Colitis in India

15 Dec 2022 , 11:38 AM

Biocon Limited has announced the start of a clinical trial of Itolizumab in patients with Ulcerative Colitis (UC) in India, in collaboration with Equillium Inc.

This is a two-treatment period, phase two, randomised, double-blind, parallel-group, placebo, and active-controlled (adalimumab) study to assess the safety and efficacy of Itolizumab for inducing remission in biologics-naive patients with moderate to severely active UC.

“We are encouraged by the progress being made on our high-value, multi-indication molecule, Itolizumab, in partnership with Equillium,” said Siddharth Mittal, Managing Director and CEO of Biocon Limited.

He added, “the start of Phase 2 clinical study, which will determine its efficacy for the treatment of Ulcerative Colitis, is a crucial step ahead in the company’s efforts to deliver benefits to patients suffering from this disease in India.”

The study, which has been approved by the Drugs Controller General of India (DCGI), will include several tertiary hospitals that specialise in treating UC patients. On December 1, 2022, the first patient who intended to participate in the study was screened.

At around 10.55 AM, Biocon was trading at Rs270.15 down by 0.55% from its previous closing of Rs271.65 on the BSE. The scrip opened at Rs272.05 and touched an intraday high and low of Rs273.65 and Rs269.50 respectively. 

For feedback and suggestions, write to us at [e-mail]